醋酸乌利司他治疗子宫肌瘤的上市许可与临床实施评价
本文评述醋酸乌利司他(UPA)治疗子宫肌瘤的上市许可与临床实施过程。PEARL I和II随机对照试验后于2012年获批用于术前治疗,PEARL III和IV观察性试验后获批间歇治疗;因与肝损伤的明显关联,UPA于2017年和2020年暂时停用。本文指出PEARL试验人群代表性有限、未评估手术结局、间歇治疗无对照组,而欧洲和加拿大5年内处方达90万个治疗周期。
要点
- PEARL试验研究人群代表性有限,未评估手术结局,间歇治疗无对照组。
- 欧洲和加拿大5年内处方90万个UPA治疗周期,临床实施广泛。
- UPA因与肝损伤的明显关联于2017年和2020年暂时停用。
核心结论
- 作者认为,上市后营销实施应规范,以在广泛处方新药前生成必要证据,所有利益相关方应认识并承担各自责任。
研究设计与样本
- 本文为临床意见论文,评述UPA的上市许可与实施过程,并纳入PEARL I和II随机对照试验及PEARL III和IV观察性试验。
主要发现
- 欧洲药品管理局(EMA)要求III期注册试验在代表性人群中评估相关结局并与金标准治疗比较。
- 本文显示所有PEARL试验的研究人群代表性有限,未评估手术结局,间歇治疗无对照组评估。
- 欧洲和加拿大合计5年内处方90万个治疗周期,临床实施广泛。
- UPA因与肝损伤的明显关联于2017年和2020年暂时停用。
- 开发和评估新药上市前研究涉及极高成本,影响试验设计及所选结局的相关性,从而妨碍临床适用性。
关键数值与推荐
- EMA要求III期注册试验在代表性人群中评估相关结局,并与金标准治疗比较。
- UPA于2012年在PEARL I和II随机对照试验后获批用于手术前治疗。
- UPA在PEARL III和IV观察性试验后获批用于间歇治疗。
临床怎么用
- 作者认为,上市后营销实施应规范,以在广泛处方新药前生成必要证据。
- 作者认为,所有利益相关方,从制药公司到授权机构、政府资助机构和医疗专业人员,应认识并承担各自责任。
局限性
- 本文显示所有PEARL试验的研究人群代表性有限。
- 本文显示手术结局未评估。
- 本文显示间歇治疗无对照组评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ulipristal acetate (UPA) is a medical treatment for uterine fibroids and was authorized for surgical pre-treatment in 2012 after the conduct of the PEARL I and II randomized controlled trials and for intermittent treatment after the observational PEARL III and IV trials. However, UPA came into disrepute due to its temporary suspension in 2017 and 2020 because of an apparent association with liver injury. This clinical opinion paper aims to review the process of marketing authorization and implementation of UPA, in order to provide all involved stakeholders with recommendations for the introduction of future drugs. Before marketing authorization, the European Medicines Agency (EMA) states that Phase III registration trials should evaluate relevant outcomes in a representative population, while comparing to gold-standard treatment. This review shows that the representativeness of the study populations in all PEARL trials was limited, surgical outcomes were not evaluated and intermittent treatment was assessed without comparative groups. Implementation into clinical practice was extensive, with 900 000 prescribed treatment cycles in 5 years in Europe and Canada combined. Extremely high costs are involved in developing and evaluating pre-marketing studies in new drugs, influencing trial design and relevance of chosen outcomes, thereby impeding clinical applicability. It is vitally important that the marketing implementation after authorization is regulated in such way that necessary evidence is generated before widespread prescription of a new drug. All stakeholders, from pharmaceutical companies to authorizing bodies, governmental funding bodies and medical professionals should be aware of their role and take responsibility for their part in this process.
引用
- Middelkoop MA, de Lange ME, Clark TJ, et al. Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids. Hum Reprod. 2022. PMID: 35143669. doi:10.1093/humrep/deac009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。